Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19 : A double-blind placebo-controlled clinical trial
© 2022 John Wiley & Sons, Ltd..
Considering the outbreak pandemic of Coronavirus Disease 2019 (COVID-19), the lack of effective therapeutic strategies for the management of this viral disease, and the increasing evidence on the antiviral potential of silymarin, this study aimed to investigate the effectiveness of silymarin nanomicelles on the symptom's resolution time, laboratory parameters, and liver enzymes in patients with COVID-19. The participants were assigned to the nano-silymarin (n = 25) (receiving SinaLive soft gel, containing 70 mg silymarin as nanomicelles) or placebo groups (n = 25) three times daily for two weeks. Patients' symptoms and laboratory findings were assessed at baseline and during the follow-up period (one week and one month after the beginning of the treatment). No significant differences were observed between the two groups in terms of symptoms resolution time, laboratory parameters, and hospitalization duration (p > 0.05). However, the alanine aminotransferase level decreased significantly in the treatment group, compared to the placebo group (p < 0.001). Concomitant use of dexamethasone and remdesivir with silymarin might make the effects of silymarin on the improvement of patients' condition unclear. Further clinical trials are recommended with diverse dosages and larger sample sizes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Phytotherapy research : PTR - 36(2022), 10 vom: 03. Okt., Seite 3924-3931 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aryan, Hossein [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 13.10.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ptr.7537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343793490 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343793490 | ||
| 003 | DE-627 | ||
| 005 | 20231226021255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ptr.7537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343793490 | ||
| 035 | |a (NLM)35859298 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aryan, Hossein |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19 |b A double-blind placebo-controlled clinical trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons, Ltd. | ||
| 520 | |a Considering the outbreak pandemic of Coronavirus Disease 2019 (COVID-19), the lack of effective therapeutic strategies for the management of this viral disease, and the increasing evidence on the antiviral potential of silymarin, this study aimed to investigate the effectiveness of silymarin nanomicelles on the symptom's resolution time, laboratory parameters, and liver enzymes in patients with COVID-19. The participants were assigned to the nano-silymarin (n = 25) (receiving SinaLive soft gel, containing 70 mg silymarin as nanomicelles) or placebo groups (n = 25) three times daily for two weeks. Patients' symptoms and laboratory findings were assessed at baseline and during the follow-up period (one week and one month after the beginning of the treatment). No significant differences were observed between the two groups in terms of symptoms resolution time, laboratory parameters, and hospitalization duration (p > 0.05). However, the alanine aminotransferase level decreased significantly in the treatment group, compared to the placebo group (p < 0.001). Concomitant use of dexamethasone and remdesivir with silymarin might make the effects of silymarin on the improvement of patients' condition unclear. Further clinical trials are recommended with diverse dosages and larger sample sizes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a anti-viral | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a silymarin | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Silymarin |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Alanine Transaminase |2 NLM | |
| 650 | 7 | |a EC 2.6.1.2 |2 NLM | |
| 700 | 1 | |a Farahani, Ramin Hamidi |e verfasserin |4 aut | |
| 700 | 1 | |a Chamanara, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Elyasi, Sepideh |e verfasserin |4 aut | |
| 700 | 1 | |a Jaafari, Mahmoud Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Mahboubeh |e verfasserin |4 aut | |
| 700 | 1 | |a Sani, Ashraf Tavanaee |e verfasserin |4 aut | |
| 700 | 1 | |a Ardalan, Mohamed Afshar |e verfasserin |4 aut | |
| 700 | 1 | |a Mosaed, Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Phytotherapy research : PTR |d 1996 |g 36(2022), 10 vom: 03. Okt., Seite 3924-3931 |w (DE-627)NLM08871747X |x 1099-1573 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:10 |g day:03 |g month:10 |g pages:3924-3931 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ptr.7537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 10 |b 03 |c 10 |h 3924-3931 | ||